Was macht Oncternal Therapeutics?
Unternehmensprofil
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Chart der Oncternal Therapeutics Aktie
Charttool öffnen
Aktuelle Nachrichten zu Oncternal Therapeutics
Weitere Nachrichten
Das berichten andere über Oncternal Therapeutics
Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology...
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt
und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.